Xiangmin Cui - 17 Sep 2021 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC.

Role
Director, 10%+ Owner
Signature
/s/ James Paul Rickey, attorney-in-fact
Issuer symbol
N/A
Transactions as of
17 Sep 2021
Net transactions value
+$14,499,998
Form type
4
Filing time
21 Sep 2021, 17:12:50 UTC
Next filing
23 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALPN Common Stock Purchase $14,499,998 +1,542,553 +49% $9.40 4,708,288 17 Sep 2021 See Footnote F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reportable securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). The Reporting Person is the manager of the general partner of the Fund. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interests therein.